SKIN — The Beauty Health Company

Summary of Beauty Health Company (SKIN) Q3 2025 Earnings Call

1. Key Financial Results and Metrics

• Total Net Sales: $70.7 million, down 10.3% year-over-year, slightly above the high end of guidance.
• Device Segment Revenue: $20.8 million, a decrease of 24.6% year-over-year, attributed to global equipment sales pressure and a transition in the China market.
• Consumables Segment Revenue: $49.8 million, down 2.6% year-over-year; excluding China impact, sales would have increased modestly.
• Adjusted Gross Margin: 68%, a decline of 150 bps year-over-year due to lower average selling prices.
• Adjusted EBITDA: $8.9 million, up 11% year-over-year, reflecting cost control and operational execution.
• Operating Loss: $6.2 million, improved from a loss of $21.5 million in Q3 2024.
• Cash Position: $219.4 million, down from $370.1 million at year-end 2024, primarily due to debt refinancing activities.

2. Strategic Updates and Business Highlights

• Leadership Transition: CEO Pedro Malha emphasized the importance of operational excellence and a clear strategy for growth.
• Focus Areas: The company will prioritize:
  1. Protecting and growing the Hydrafacial installed base (over 35,000 devices).
  2. Driving consumable utilization to enhance profitability.
  3. Continuous innovation in devices and consumables.
  4. Strengthening operational discipline in commercial execution and cost control.
• Product Launches: Successful introduction of new products, contributing to a 14% growth in booster sales.

3. Forward Guidance and Outlook

• Revenue Guidance for FY 2025: Increased to between $293 million and $300 million.
• Adjusted EBITDA Guidance: Raised to between $37 million and $39 million.
• Q4 Expectations: Projecting net sales between $74.5 million and $81.5 million and adjusted EBITDA between $6.9 million and $8.9 million.

4. Bad News, Challenges, or Points of Concern

• Declining Device Sales: Continued pressure on device sales, particularly in the Americas and APAC regions, with a noted 41.5% decline in APAC revenue.
• Churn Rate: Increased churn at 1.8%, attributed to financial pressures on low-volume providers, leading to closures and inconsistent device utilization.
• Macroeconomic Pressures: Ongoing inflation, financing challenges, and uneven consumer confidence affecting discretionary spending in the beauty sector.
• Operational Challenges: Transitioning from a direct sales model to a distributor model in China has impacted sales.

5. Notable Q&A Insights

• Regional Dynamics: The Americas, accounting for 65% of revenue, saw a 7% decline, but stabilization is noted. EMEA remained flat, with strong performance in Germany.
• International Strategy: The company will continue to leverage a distributor network while investing in education and training to enhance market penetration.
• Consumer Trends: There is a shift towards less invasive treatments, impacting the performance of plastic surgeons while med spas continue to drive market growth.
• Pricing Power: A recent 5% price increase on consumables was well-received, contributing to higher average selling prices.
• Future Focus: Emphasis on driving top-line growth while maintaining profitability, with a commitment to innovation in consumables and better support for providers to reduce churn.

This summary encapsulates the key points from the earnings call, highlighting both the progress and challenges faced by Beauty Health Company as it navigates a complex market landscape.